Home Cart Sign in  
Chemical Structure| 476-66-4 Chemical Structure| 476-66-4

Structure of Ellagic acid
CAS No.: 476-66-4

Chemical Structure| 476-66-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ellagic acid is a potent and cell permeable casein kinase 2 (CK2) inhibitor with Ki of 20 nM, acts as a potent antioxidant and anti-mutagenic.

Synonyms: Gallogen; Elagostasine; HSDB 7574

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ellagic acid

CAS No. :476-66-4
Formula : C14H6O8
M.W : 302.19
SMILES Code : O=C1C2=CC(O)=C(O)C(O3)=C2C4=C(O1)C(O)=C(O)C=C4C3=O
Synonyms :
Gallogen; Elagostasine; HSDB 7574
MDL No. :MFCD00006914
InChI Key :AFSDNFLWKVMVRB-UHFFFAOYSA-N
Pubchem ID :5281855

Safety of Ellagic acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Ellagic acid

DNA
Hedgehog
TLR

Isoform Comparison

Biological Activity

Target
  • Topo I

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00788866 Intrauterine Growth Restrictio... More >>n Less << Not Applicable Completed - United States, Missouri ... More >> St Louis Children's Hospital St Louis, Missouri, United States, 63110 Less <<
NCT02333461 Overweight Ob... More >>esity Less << Not Applicable Completed - -
NCT03140280 Myelodysplastic Syndromes Phase 2 Recruiting April 1, 2020 United States, Wisconsin ... More >> Froedtert & the Medical College of Wisconsin Recruiting Milwaukee, Wisconsin, United States, 53226 Contact: Ehab Atallah, MD    414-805-4600    eatallah@mcw.edu    Contact: Medical College of Wisconsin Cancer Center Clinical Trials Office    414-805-8900    cccto@mcw.edu Less <<
NCT02935777 Mental Processes Phase 1 Completed - United Kingdom ... More >> Queen Margaret University Edinburgh, Scotland, United Kingdom, EH21 6UU Less <<
NCT03482401 Breast Cancer Not Applicable Active, not recruiting June 1, 2019 Spain ... More >> Hospital General Universitario Reina Sofía Murcia, Spain, 30003 Less <<
NCT00455416 Follicular Lymphoma Phase 2 Unknown December 2009 Norway ... More >> RRHF RIkshospitalet Radiumhospitalet HF Recruiting Montebello, Oslo, Norway, 0310 Contact: Kjell Magne Russnes, MD    +4722934000    k.m.russnes@medisin.uio.no    Contact: Harald JR Holte, MD, PhD    +4722934000    harald.holte@radiumhospitalet.no    Principal Investigator: Harald Jr Holte, Md, PhD          Sub-Investigator: Kjell Magne Russnes, MD Less <<
NCT03535675 Adenocarcinoma of the Prostate Phase 3 Recruiting December 2021 United States, District of Col... More >>umbia Sibley Memorial Hospital Recruiting Washington, District of Columbia, United States, 20016 Contact: Channing Paller, MD    202-660-6500    cpaller1@jhmi.edu    United States, Maryland Johns Hopkins Hospital Recruiting Baltimore, Maryland, United States, 21205 Contact: Donna Dowling, RN    410-614-9526    ddowlin1@jhmi.edu    Principal Investigator: Channing Paller, MD Less <<
NCT01961869 Healthy Volunteers Phase 1 Active, not recruiting December 2019 United States, Ohio ... More >> Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less <<
NCT01249469 Solar Lentigines Not Applicable Unknown June 2011 Taiwan ... More >> National Taiwan University Hospital Recruiting Taipei, Taiwan, 100 Contact: Yi-Hua Liao, MD, PhD    886-2-23562141    yihualiao@ntu.edu.tw    Principal Investigator: Yi-Hua Liao, MD, PhD Less <<
NCT03318042 Genotype, Metabotype and Dieta... More >>ry Habits Less << Not Applicable Completed - Spain ... More >> Cebas-Csic Murcia, Spain, 30100 Less <<
NCT01916239 Colorectal Cancer Phase 1 Phase 2 Completed - Spain ... More >> Hospital General Universitario Reina Sofía Murcia, Spain, 30003 Less <<
NCT01705093 Childhood Obesity ... More >> Cardiovascular Disease Less << Phase 2 Completed - United States, California ... More >> Ragle Human Nutrition Research Center, Academic Surge, UC Davis Davis, California, United States, 95616 Less <<
NCT03548701 - Recruiting May 21, 2020 United States, New York ... More >> Mount Sinai Hospital Recruiting New York, New York, United States, 10029 Contact: Patrick Maher, MD    404-550-9559    patrick.maher@mountsinai.org    Contact: Daniel Katz, MD    732-322-6675    daniel.katz@mountsinai.org    Principal Investigator: Patrick Maher, MD Less <<
NCT02056496 Healthy Phase 1 Completed - Spain ... More >> UCAM (San Antonio Catholic University from Murcia) Murcia, Spain, 30107 Less <<
NCT02263378 HPV Infection Not Applicable Completed - -
NCT03713164 Healthy Phase 1 Phase 2 Completed - United States, California ... More >> UCLA Center for Human Nutrition, 900 Veteran Ave. Los Angeles, California, United States, 90095 Less <<
NCT02370641 Urolith Not Applicable Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.31mL

0.66mL

0.33mL

16.55mL

3.31mL

1.65mL

33.09mL

6.62mL

3.31mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories